FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Viatris's Trailing 12-Month Free Cash Flow is $2,325 Mil, and Market Cap is $13,740 Mil. Therefore, Viatris's FCF Yield % for today is 16.92%.
The historical rank and industry rank for Viatris's FCF Yield % or its related term are showing as below:
VTRS'
s FCF Yield % Range Over the Past 10 Years
Min: 0.71 Med: 7.3 Max: 28.7
Current: 16.92
During the past 13 years, the highest FCF Yield % of Viatris was 28.70%. The lowest was 0.71%. And the median was 7.30%.
VTRS's FCF Yield % is ranked better than 95.46% of 1080
companies
in the Drug Manufacturers industry
Industry Median: -0.655
vs VTRS: 16.92
The historical data trend for Viatris's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris's FCF Yield % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Viatris's FCF Yield % falls into.
Viatris FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Viatris's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Viatris FCF Yield % Related Terms
Thank you for viewing the detailed overview of Viatris's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your 